Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 387

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 387
---
3                         |     |                                     2,938 |     |              – |     |                      3 |   |     |       2,941 |   |
| At 31 December 2022                         |     |                                         – |     |              – |     |                      6 |   |     |           6 |   |
| At 31 December 2021                         |     |                                         – |     |              – |     |                      – |   |     |           – |   |

| F-50 |

| 11 | Intangible assets (continued) |

The individual intangible
asset which is material to the financial statements is as follows:

| Schedule of individual intangible assets |     |                 |            |     |            |     |             |     |                        |              |     |              |     |              |
|                                          |     | Carrying amount |            |     |            |     |             |     | Remaining amortisation 
 period                 |              |     |              |     |              |
|                                          |     |                 | 2023 £’000 |     | 2022 £’000 |     | 2021  £’000 |     |                        | 2023 (years) |     | 2022 (years) |     | 2021 (years) |
| MTX228 tolimidone acquired IPRD*         |     |                 |      2,938 |     | –          |     | –           |     |                        | n/a          |     | n/a          |     | n/a          |

| * | asset is not yet in use and has not started amortising |

On 21 December 2023 the Company executed an Assignment
and Exchange Agreement with Adhera for assignment of Adhera’s rights and a new licence for tolimidone (MTX228) with Melior for total
consideration of $11.12 million. The initial consideration was settled as follows:

| Schedule of purchase on intangible assets                                           |       |       |
|                                                                                     | $’000 | £’000 |
| Cash paid to Adhera                                                                 |   300 |   237 |
| 100,356 ADSs, valued at the Offer price issued to Adhera Loan Noteholders           |   201 |   159 |
| 899,642 Pre-funded warrants at the Offering price issued to Adhera Loan Noteholders | 1,799 | 1,